HIV Infections Clinical Trial
Official title:
Reducing HIV/AIDS and Drug Abuse Among Heroin Addicts Released From Compulsory Rehabilitation in China
NCT number | NCT01270100 |
Other study ID # | DA025385 |
Secondary ID | 1R21DA025385-01 |
Status | Completed |
Phase | N/A |
First received | January 4, 2011 |
Last updated | January 4, 2011 |
Verified date | December 2010 |
Source | University of California, Los Angeles |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
The purpose of the study is to develop and pilot-test a Recovery Management Intervention
(RMI) program for heroin addicts released from compulsory rehabilitation in China.
The project has the following specific aims:
Primary aims:
Aim 1. To engage key stakeholders in the local communities involved in supporting the
transition of heroin addicts released from compulsory rehabilitation to the community; Aim
2. To identify potential barriers for participating in MMT in China; Aim 3. To develop and
deliver educational/training materials on HIV risks, relapse prevention, and MMT; Aim 4. To
adapt and develop the Recovery Management Intervention (RMI) program for heroin addicts
released from compulsory rehabilitation in China; Aim 5. To conduct a pilot trial and obtain
preliminary outcome data associated with RMI, relative to enhanced standard care.
Secondary aim:
Aim 6. To explore predictors of relapse and HIV/AIDS risk behaviors.
It is hypothesized that the intervention will reduce drug use relapse and the negative
consequences associated with relapse, including HIV risk behaviors
Status | Completed |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria:The study population will be drawn from all adult patients at
participating compulsory rehabilitation facilities who: 1. have been incarcerated for at least one year and would have been eligible for MMT at the time of incarceration, 2. have at least 1 month remaining before release, 3. met the DSM-IV criteria for heroin dependence at the time of incarceration, 4. are willing to enroll in methadone maintenance treatment, and 5. are Shanghai residents who reside in the areas of Shanghai targeted by the study. Exclusion Criteria: Individuals diagnosed with severe mental illness will not be eligible to participate. |
N/A
Country | Name | City | State |
---|---|---|---|
China | Shanghai Mental Health Center | Shanghai |
Lead Sponsor | Collaborator |
---|---|
University of California, Los Angeles | National Institute on Drug Abuse (NIDA) |
China,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |